A Phase Ib, Open-Label Study Evaluating The Safety, Tolerability, and Pharmacokinetics of Onartuzumab Given as a Single Agent and in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
Price : $35 *
At a glance
- Drugs Onartuzumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Roche
- 11 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 17 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 17 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.